Biosurgery Market (2026 - 2033)

Biosurgery Market Summary

The global biosurgery market size was valued at USD 28.4 billion in 2025 and is projected to grow from USD 29.7 billion in 2026 to USD 41.0 billion in 2033, at a CAGR of 4.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.0% in 2025. Market growth is driven by increasing adoption of minimally invasive surgical procedures, continuous advancements in surgical technologies, and the rising prevalence of chronic diseases, including cancer, cardiovascular diseases, arthritis, and other non-communicable diseases. These factors are increasing the demand for products that support effective bleeding control, tissue repair, and postoperative healing during surgical procedures.

The growing geriatric population is contributing to higher demand for surgical interventions because older adults are more susceptible to chronic diseases and age-related disorders requiring surgical treatment. Biosurgery refers to the use of biologically derived products, including hemostatic agents, surgical sealants, tissue adhesives, adhesion barriers, and soft tissue repair materials, to support surgical procedures by controlling bleeding, promoting tissue healing, and reducing postoperative complications. The rising incidence of cardiovascular diseases, trauma cases, and sports-related injuries is further supporting market growth.

According to the World Health Organization (WHO), injuries and violence account for over 4.4 million deaths annually, representing nearly 8% of all deaths worldwide. Road traffic injuries account for around one-third of all injury-related deaths. The increasing burden of trauma and emergency surgical procedures is driving demand for biosurgery products used in wound management, bleeding control, tissue repair, and surgical reconstruction.

Continuous product innovation and technological advancements are expanding the adoption of biosurgery products across multiple surgical specialties. Increasing use of surgical sealants, adhesion barriers, hemostatic agents, and tissue repair products is improving surgical efficiency and patient outcomes, particularly in minimally invasive procedures. Ongoing investment in product development and advanced surgical technologies continues to support market expansion.

Analyst Perspective

The biosurgery market is experiencing steady growth due to the growing use of biologically derived products that enhance surgical efficiency and patient outcomes. Rising volumes of surgical procedures, growing preference for minimally invasive techniques, and increasing demand for effective bleeding control and tissue management continue to support product adoption. Manufacturers are focusing on developing advanced hemostatic agents, surgical sealants, adhesion barriers, and soft tissue repair products with improved biocompatibility and ease of application. At the same time, healthcare providers are emphasizing faster patient recovery, lower postoperative complications, and reduced hospital stays, increasing the use of biosurgery products across multiple surgical specialties. Continued product innovation and expansion of surgical care infrastructure are expected to create sustained growth opportunities for the global biosurgery market.

Product Insights

By product, the surgical sealants segment held the largest market share of around 26.0% in 2025. The segment dominated due to the increasing volume of surgical procedures requiring effective bleeding control and prevention of fluid and air leakage. Surgical sealants are widely used across cardiovascular, neurological, pulmonary, gastrointestinal, and general surgical procedures. Fibrin-, cyanoacrylate-, glutaraldehyde-albumin-, and polyethylene glycol-based sealants are among the most commonly used products. For instance, in October 2024, Grifols received U.S. FDA approval for its fibrin sealant solution for pediatric patients to control surgical bleeding, expanding the clinical use of fibrin-based surgical sealants.

The soft tissue attachments segment is expected to register the fastest CAGR over the forecast period. Rising adoption of minimally invasive procedures, increasing orthopedic and reconstructive surgeries, and growing incidence of trauma- and sports-related injuries are driving demand for soft tissue attachment products. These products are widely used in orthopedic, dental, plastic, reconstructive, and regenerative surgeries. According to the World Health Organization (WHO), road traffic injuries cause over 1.19 million deaths annually, while 20-50 million people sustain non-fatal injuries that often require surgical treatment and tissue reconstruction. The growing number of trauma cases is increasing demand for biosurgical soft tissue repair products.

Application Insights

By application, the general surgery segment accounted for around 30.0% of the biosurgery market in 2025. General surgical procedures, including appendectomy, colorectal surgery, hernia repair, breast surgery, vascular surgery, endocrine surgery, trauma surgery, and surgical oncology, require effective bleeding control, tissue sealing, and postoperative adhesion prevention. The high procedural volume across hospitals and ambulatory surgical centers continues to drive demand for hemostatic agents, surgical sealants, adhesion barriers, and soft tissue repair products.

The cardiovascular surgery application segment is expected to grow at the fastest CAGR during the forecast period. Rising prevalence of cardiovascular diseases, increasing cardiac surgical procedures, and growing adoption of minimally invasive cardiovascular interventions are driving demand for biosurgery products. The increasing burden of cardiovascular disease is contributing to higher demand for surgical procedures requiring hemostatic agents, surgical sealants, and tissue repair products.

Regional Insights

North America dominated the biosurgery market, accounting for the largest share of approximately 41.0% of revenue in 2025. Market growth is driven by well-established healthcare infrastructure, high healthcare expenditure, increasing adoption of minimally invasive surgical procedures, and the presence of leading biosurgery manufacturers. Rising prevalence of chronic diseases, including cardiovascular diseases and cancer, is increasing the demand for hemostatic agents, surgical sealants, adhesion barriers, and soft tissue repair products. According to the U.S. Centers for Disease Control and Prevention (CDC), a person in the U.S. experiences a heart attack approximately every 40 seconds. The high burden of cardiovascular disease is increasing the number of surgical procedures requiring biosurgery products.

The U.S. biosurgery market accounted for the largest share of the regional market in 2025. Growth is supported by advanced healthcare infrastructure, high adoption of biosurgery products, increasing surgical volumes, and continued use of minimally invasive surgical techniques. Rising prevalence of chronic diseases and increasing demand for complex surgical procedures are further supporting market growth.

Europe Biosurgery Market Trends

The Europe marketis expected to grow at the fastest CAGR during forecast period. This market growth is supported by increasing volumes of surgical procedures, expanding healthcare infrastructure, growing adoption of minimally invasive surgery, and a rising geriatric population. Continued investment in advanced surgical technologies and the availability of skilled healthcare professionals are further supporting demand for biosurgery products across the region.

The Germany biosurgery market is expected to grow significantly over the forecast period. Rising orthopedic, cardiovascular, and general surgical procedures, increasing prevalence of chronic diseases, and continued adoption of advanced surgical technologies are supporting demand for biosurgery products across hospitals and surgical centers.

Key Biosurgery Market Company Insights

The biosurgery market is characterized by established medical device and life sciences companies focusing on product innovation, strategic collaborations, acquisitions, and portfolio expansion to strengthen their presence across hemostatic agents, surgical sealants, adhesion barriers, and soft tissue repair products. Companies continue to invest in biologic technologies that improve surgical outcomes and support minimally invasive procedures across multiple surgical specialties. 

Key Biosurgery Companies

The following key companies have been profiled for this study on the biosurgery market:

• Sanofi

• Baxter

• INTEGRA LIFESCIENCES

• Medtronic

• B. Braun SE

• Pfizer Inc

• Stryker

• Johnson & Johnson Services, Inc

• BD

• Artivion, Inc (CryoLife, Inc.)

Recent Developments

• In January 2025, Medtronic entered into a five-year exclusive partnership with Kuros Biosciences to commercialize MagnetOs bone graft across selected spine surgery markets. The partnership expands Medtronic's portfolio of biologic solutions used in spinal fusion procedures.

• In April 2025, Baxter launched the room-temperature HEMOPATCH Sealing Hemostat in Europe. The absorbable collagen pad is designed for hemostasis and tissue sealing during both open and minimally invasive surgical procedures. The product offers room-temperature storage and an extended shelf life, improving operating room accessibility and supporting the use of advanced biosurgery products across multiple surgical specialties.

Biosurgery Market Report Scope

Global Biosurgery Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the biosurgery market report based on product, application, and region. 

• Product Outlook (Revenue, USD Billion, 2021 - 2033)

  • Surgical sealants

  • Hemostatic agents

  • Adhesion barriers

  • Soft Tissue attachments

  • Bone graft attachments

  • Others

• Application Outlook (Revenue, USD Billion, 2021 - 2033)

  • General surgery

  • Orthopedic surgery

  • Cardiovascular surgery

  • Neurological surgery

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait